Lantheus Holdings LNTH
Lantheus Holdings FY 2024: revenue $1.5B, up 18%; diluted EPS $4.36
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001628280-25-007970
- Document
- 10-K
- Exhibit 4.2
- Warrants or notes
- Exhibit 10.32
- Material contract
- Exhibit 10.35
- Material contract
- Exhibit 10.36
- Material contract
- Exhibit 10.37
- Material contract
Key figures from this report
These are the numbers Lantheus Holdings reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$1.5B+18% from $1.3B in FY 202310-K income statement, on EDGAR
- Net income$312.4M−4% from $326.7M in FY 202310-K income statement, on EDGAR
- Diluted EPS$4.36−6% from $4.65 in FY 202310-K income statement, on EDGAR
- Cash and cash equivalents$912.8M+28% from $713.7M in FY 202310-K balance sheet, on EDGAR
- Cash from operations$544.8M+78% from $305.3M in FY 202310-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.
- Adma Biologics ADMA public float $4.2B, Jun 30, 2025
- Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025
- Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025
- Halozyme Therapeutics HALO public float $4.5B, Jun 30, 2025
- Alkermes ALKS public float $4.7B, Jun 30, 2025